Lumexa Imaging Announces Pricing of Initial Public Offering

Rhea-AI Summary

Lumexa Imaging (NASDAQ: LMRI) priced its initial public offering of 25,000,000 shares of common stock at $18.50 per share, with a 30‑day underwriter option for up to 3,750,000 additional shares.

The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol LMRI on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to customary closing conditions. The registration statement on Form S‑1 was declared effective by the SEC on December 10, 2025.

Positive

• Offer size: 25,000,000 shares priced at $18.50
• Overallotment: 30‑day option for 3,750,000 additional shares
• Listing: Expected Nasdaq Global Select listing under LMRI on Dec 11, 2025
• Regulatory: S‑1 declared effective by the SEC on Dec 10, 2025

Negative

• None.

Key Figures

IPO shares offered: 25,000,000 shares IPO price: $18.50 per share Underwriter option: 3,750,000 shares +5 more

8 metrics

IPO shares offered 25,000,000 shares Initial public offering common stock size

IPO price $18.50 per share Public offering price for common stock

Underwriter option 3,750,000 shares 30-day option to purchase additional shares

Par value $0.001 per share Par value of common stock

Nasdaq symbol LMRI Expected Nasdaq Global Select Market listing symbol

Form S-1 effective date December 10, 2025 SEC effectiveness of registration statement

Expected trading start December 11, 2025 Expected first trading day on Nasdaq Global Select Market

Expected offering close December 12, 2025 Expected closing date, subject to customary conditions

Market Reality Check

Price: $13.97 Vol: Volume 6,732,775 matches ...

normal vol

$13.97 Last Close

Volume Volume 6,732,775 matches the 20-day average of 6,732,775, typical for an IPO listing day baseline. normal

Market Pulse Summary

This announcement details Lumexa Imaging’s IPO, including 25,000,000 shares of common stock priced a...

Analysis

This announcement details Lumexa Imaging’s IPO, including 25,000,000 shares of common stock priced at $18.50 per share and a 30-day underwriter option for up to 3,750,000 additional shares. The registration statement on Form S-1 was declared effective on December 10, 2025, with trading expected on the Nasdaq Global Select Market under "LMRI". Investors may focus on post-listing liquidity, execution of the offering, and any future updates to the company’s capital or regulatory disclosures via the SEC.

Key Terms

initial public offering, prospectus, registration statement on Form S-1, Nasdaq Global Select Market, +1 more

5 terms

initial public offering financial

"announced today the pricing of its initial public offering of 25,000,000 shares"

An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.

prospectus regulatory

"The offering of Lumexa Imaging's Common Stock is being made only by means of a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

registration statement on Form S-1 regulatory

"A registration statement on Form S-1 relating to the Common Stock was declared effective"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

Nasdaq Global Select Market financial

"begin trading on the Nasdaq Global Select Market under the symbol "LMRI""

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

book-running managers financial

"Barclays, J.P. Morgan and Jefferies are acting as joint lead book-running managers."

Book-running managers are the main banks or financial firms that organize and oversee a company's sale of new stocks or bonds. They help set the price, decide how many to sell, and coordinate the process to make sure everything runs smoothly. Their role is important because they guide the company through the complex process of raising money from investors.

AI-generated analysis. Not financial advice.

RALEIGH, N.C., Dec. 10, 2025 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") announced today the pricing of its initial public offering of 25,000,000 shares of its common stock, par value $0.001 per share (the "Common Stock"), at a price to the public of $18.50 per share of Common Stock. In connection with the offering, Lumexa Imaging has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of its Common Stock. The Common Stock is expected to begin trading on the Nasdaq Global Select Market under the symbol "LMRI" on December 11, 2025, and the offering is expected to close on December 12, 2025, subject to the satisfaction of customary closing conditions.

Barclays, J.P. Morgan and Jefferies are acting as joint lead book-running managers. Deutsche Bank Securities and Wells Fargo Securities are acting as book-running managers. Leerink Partners, William Blair, Capital One Securities, Fifth Third Securities and Raymond James are acting as bookrunners. PNC Capital Markets LLC, Academy Securities, Loop Capital Markets and R. Seelaus & Co., LLC are acting as co-managers.

The offering of Lumexa Imaging's Common Stock is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting EDGAR on the U.S. Securities and Exchange Commission (the "SEC") website at www.sec.gov. Alternatively, copies of the final prospectus, when available, may be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at prospectus_department@jefferies.com.

A registration statement on Form S-1 relating to the Common Stock was declared effective by the SEC on December 10, 2025. This press release does not constitute an offer to sell or the solicitation of an offer to buy Common Stock, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

ABOUT LUMEXA IMAGING

Lumexa Imaging is a nationwide provider of diagnostic imaging services. As of September 30, 2025, we and our affiliates operated the second largest outpatient imaging center footprint in the United States. It spans 184 centers across 13 states and includes eight joint venture partnerships with health systems.

MEDIA CONTACT

Melissa Weston
corpcomms@lumexaimaging.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumexa-imaging-announces-pricing-of-initial-public-offering-302638582.html

SOURCE Lumexa Imaging

FAQ

How many shares did Lumexa Imaging (LMRI) offer in its IPO and at what price?

Lumexa Imaging offered 25,000,000 shares at $18.50 per share.

What is the Nasdaq ticker and expected first trading date for Lumexa Imaging (LMRI)?

The Common Stock is expected to trade under LMRI on the Nasdaq Global Select Market starting December 11, 2025.

Did Lumexa Imaging (LMRI) grant an overallotment option in the IPO?

Yes, the company granted underwriters a 30‑day option to purchase up to 3,750,000 additional shares.

When is the Lumexa Imaging (LMRI) IPO expected to close?

The offering is expected to close on December 12, 2025, subject to customary closing conditions.

Has the SEC declared Lumexa Imaging's registration statement effective for the IPO (LMRI)?

Yes, the Form S‑1 registration statement was declared effective by the SEC on December 10, 2025.